These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 1746075)

  • 1. [Hormone kinetics in suppression with monthly Enantone depot preparations].
    Schilling A
    Urologe A; 1991 May; 30(3 Suppl):9. PubMed ID: 1746075
    [No Abstract]   [Full Text] [Related]  

  • 2. [Galenic innovation: Enantone monthly depot preparations].
    Hübner R
    Urologe A; 1991 May; 30(3 Suppl):7-8. PubMed ID: 1746074
    [No Abstract]   [Full Text] [Related]  

  • 3. [First national Enantone Symposium. Progress in therapy of prostatic cancer. Multicenter study: long-term follow-up].
    Fornara P
    Urologe A; 1991 May; 30(3 Suppl):10-2. PubMed ID: 1746070
    [No Abstract]   [Full Text] [Related]  

  • 4. [LHRH analogs as monthly depot preparations in treatment of advanced prostate cancer].
    Urologe A; 1991 May; 30(3 Suppl):2-3. PubMed ID: 1746071
    [No Abstract]   [Full Text] [Related]  

  • 5. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?
    Cox MC; Scripture CD; Figg WD
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):605-11. PubMed ID: 16111462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer.
    Sharifi R; Browneller R;
    J Urol; 2002 Sep; 168(3):1001-4. PubMed ID: 12187208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.
    Robinson MR; Denis L; Mahler C; Walker K; Stitch R; Lunglmayr G
    Eur J Surg Oncol; 1985 Jun; 11(2):159-65. PubMed ID: 3159598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of metastatic prostatic cancer with monthly injections of leuprolide acetate depot].
    Jiménez Cruz JF; Vera Donoso CD; Iborra I; Solsona E; Forner E; Villavicencio H; Díaz C; González C; Rioja L; Pertusa C
    Actas Urol Esp; 1994 Feb; 18(2):90-3. PubMed ID: 7976707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose-response evaluation.
    Mazzei T; Mini E; Eandi M; Reali EF; Fioretto L; Bartoletti R; Rizzo M; Calabrò G; Periti P
    Drugs Exp Clin Res; 1989; 15(8):373-87. PubMed ID: 2513176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re: Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration.
    Dearnaley DP; Norman AR; Shahidi M
    J Urol; 1999 Jul; 162(1):170. PubMed ID: 10379777
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety and clinical efficacy of a new 6-month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe.
    Tunn UW; Wiedey K
    Prostate Cancer Prostatic Dis; 2009; 12(1):83-7. PubMed ID: 19030021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How should we understand the term androgen deprivation therapy?
    Drewa T; Soloway MS
    Eur Urol; 2012 Apr; 61(4):856. PubMed ID: 22266269
    [No Abstract]   [Full Text] [Related]  

  • 13. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS; Pacificar JS; Shapiro CE; Williams SG
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expert opinion on 6-monthly luteinizing hormone-releasing hormone agonist treatment with the single-sphere depot system for prostate cancer.
    Schulman C; Alcaraz A; Berges R; Montorsi F; Teillac P; Tombal B
    BJU Int; 2007 Jul; 100 Suppl 1():1-5. PubMed ID: 17593201
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy over time of LHRH analogs in the treatment of PCa--a prospective analysis using serum testosterone to determine dosing intervals.
    Greil S; Robinson EA; Singal B; Kleer E
    Urology; 2009 Mar; 73(3):631-4. PubMed ID: 19110301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of uterine leiomyoma with depot leuprorelin acetate (Enantone-Gyn monthly depot). Effect on leiomyoma volume and operability. German Leuprorelin Study Group].
    Stolz W; Pfützenreuter N
    Zentralbl Gynakol; 1997; 119(10):468-75. PubMed ID: 9432825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmaceutical aspects. Nasal and depot formulations of leuprolide.
    Shimamoto T
    J Androl; 1987; 8(1):S14-6. PubMed ID: 3104262
    [No Abstract]   [Full Text] [Related]  

  • 18. 'Acute on chronic' effect of depot leuprolide in patients with stage D2 cancer of prostate.
    Sharifi R; Soloway M; Clayton M; Mounzer A; Strub M; Siami P; Lee M
    Anticancer Drugs; 1990 Oct; 1(1):29-31. PubMed ID: 2131032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration.
    Meinhardt W; Horenblas S
    J Urol; 1999 Jul; 162(1):170-1. PubMed ID: 10379778
    [No Abstract]   [Full Text] [Related]  

  • 20. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
    Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
    Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.